Bởi Maksym Misichenko · Nasdaq ·
Các tác nhân AI nghĩ gì về tin tức này
Despite strong fundamentals like 75% recurring revenue and 17% procedure growth, the panel is cautious due to high valuation (51x forward P/E), potential slowdown in procedure volumes, rising competition, and the risk of margin compression from new robotic platforms.
Rủi ro: High valuation and potential slowdown in procedure volumes or margin compression due to competition.
Cơ hội: None explicitly stated.
Phân tích này được tạo bởi đường dẫn StockScreener — bốn LLM hàng đầu (Claude, GPT, Gemini, Grok) nhận các lời nhắc giống hệt nhau với các biện pháp bảo vệ chống ảo tưởng tích hợp. Đọc phương pháp →
Intuitive Surgical is a leader in robotic surgery.
The company's da Vinci system continues to sell well, and patient demand remains strong.
Historically speaking, the large stock decline in 2026 isn't unusual.
Intuitive Surgical (NASDAQ: ISRG) is a very particular kind of stock. It pays no dividend, so income investors won't appreciate today's investment opportunity. It isn't cheap, so value investors will not like it either. It is a growth stock, most appropriate for those with a more aggressive streak.
The opportunity today is Intuitive Surgical's roughly 30% decline in stock price since the start of 2026. Here's why this drawdown may be a rare buying opportunity for this top surgical robotics stock.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Intuitive Surgical makes the da Vinci surgical robot system. At the end of the first quarter of 2026, there were 11,395 systems in place around the world, up 12% from the first quarter of the previous year. Simply put, despite the stock decline, the medical device maker's product continues to sell well.
However, there's a second measure that's worth considering. The number of procedures using a da Vinci system increased 17% year over year. That means that more and more surgeries are being performed with a da Vinci robot. So patient demand is strong, as well.
These trends will ebb and flow from quarter to quarter. However, the big picture is very clear. Intuitive Surgical's business is fundamentally sound. This is why investors are willing to pay a premium for the stock. Its price-to-earnings ratio is a lofty 51x, a figure that will only interest more aggressive growth investors. That said, the P/E is well below its five-year average of 70x.
What's interesting here, however, is that Intuitive Surgical generates only about 25% of its revenue from da Vinci system sales. The rest comes from what amounts to parts (instruments and accessories) and services. That is the flywheel of the business, and given the demand for robotic surgery, it is an annuity-like revenue stream. That revenue stream grows more attractive with each new da Vinci installation. This isn't just a fundamentally sound business; it is a strong business. And the da Vinci system continues to evolve, gaining regulatory approval for use in more and more types of surgery. That offers another avenue for long-term growth.
And yet the stock has fallen 30% in a very short period of time. Growth investors need to step back and put that drop into perspective. As the chart below highlights, this healthcare company's stock has declined by at least 30% eight times since its initial public offering. It recovered after each drop and went on to post new highs. While there's no way to know if that will happen this time, and some of the drops went well beyond 30%, if history is any guide, this drawdown will be temporary.
Stepping in while Intuitive Surgical's shares appear to be in free fall won't be easy. It requires a great deal of faith in the business's underlying strength. But the sale of new systems remains robust, and parts and services revenue is driven by the still strong demand among patients for robotic surgery. Even if sales of new da Vinci systems slow, the large installed base will still generate significant revenue for the company.
Intuitive Surgical's business isn't likely to fall off a cliff, which means this drawdown could be another temporary blip in the stock's long-term uptrend. Such drawdowns have happened before, but they aren't exactly everyday events. Which is why more aggressive growth investors may want to take advantage of what appears to be a rare buying opportunity in this top robotic surgery stock.
Before you buy stock in Intuitive Surgical, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Intuitive Surgical wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $463,900! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,294,401!
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 31, 2026. *
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends the following options: long January 2028 $520 calls on Intuitive Surgical and short January 2028 $530 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Bốn mô hình AI hàng đầu thảo luận bài viết này
"ISRG's premium valuation leaves scant margin of safety if utilization growth moderates from 17%."
The article correctly flags ISRG's durable flywheel—only 25% of revenue from system sales, with instruments and services providing annuity-like growth tied to an 11,395-unit installed base. Yet it underplays the 51x P/E against still-elevated growth expectations; any slowdown in procedure volumes below the recent 17% rate would compress multiples quickly. Historical 30% drawdowns have recovered, but those occurred in lower-valuation regimes. Current macro pressure on elective procedures and rising competition from newer robotic platforms are omitted risks that could extend the 2026 decline.
If procedure growth holds above 15% and new system placements accelerate, the 51x multiple could re-rate higher rather than contract, validating the dip as temporary.
"ISRG's business durability is real, but the article provides no evidence that the 30% decline was unjustified rather than a necessary multiple compression on a previously overvalued growth stock."
ISRG's 30% drawdown is real, but the article conflates historical resilience with inevitable recovery. Yes, 75% of revenue is recurring (instruments/services on 11,395 installed systems), and procedure volume grew 17% YoY—strong fundamentals. But at 51x forward P/E, we're pricing in flawless execution. The article never asks: *why* did the stock fall 30% if nothing changed? Either the market repriced growth expectations downward (suggesting prior overvaluation), or there's deteriorating guidance the article omits. A 51x multiple requires 20%+ sustained EPS growth; any slowdown in procedure adoption or margin compression becomes catastrophic. Historical 30% drawdowns recovered, but that's survivorship bias—not every stock recovers.
If the market repriced ISRG from 70x to 51x P/E on fundamentals that remain 'sound,' that's rational de-risking, not panic. The article assumes the stock *must* recover because it has before, ignoring that competitive pressure (Stryker, Medtronic advancing robotics) or regulatory headwinds could be structural, not cyclical.
"ISRG's premium valuation is only justified if they maintain their monopoly-like pricing power on recurring revenue amidst intensifying competition from Medtronic and J&J."
Intuitive Surgical (ISRG) remains a high-quality compounder, but the 51x forward P/E is a dangerous anchor in a high-rate environment. While the recurring revenue from instruments and services (75% of total) provides a defensive moat, the article ignores the rising competitive threat from Medtronic’s Hugo and Johnson & Johnson’s Ottava platforms. If these competitors gain meaningful traction, ISRG’s pricing power on replacement parts—the engine of their margin expansion—could face margin compression. A 30% drawdown is historically 'normal' for ISRG, but relying on historical volatility patterns ignores the current shift toward cheaper, open-architecture robotic alternatives that could disrupt their long-term dominance.
The 'annuity' model of instrument sales is so sticky that switching costs effectively lock hospitals into the da Vinci ecosystem for the next decade, rendering competitor entry a long-term threat rather than a near-term margin risk.
"High valuation plus capex sensitivity and potential regulatory/reimbursement headwinds risk near-term multiple compression even as the installed base grows."
Intuitive Surgical's 30% 2026 drawdown with 17% YoY procedure growth and a growing installed base looks appealing, but several risks are glossed over. The stock sits at roughly 51x earnings, leaving little cushion if growth slows or if hospitals throttle capex. Revenue is highly reliant on instruments, services, and maintenance tied to existing systems; a slowdown in new da Vinci installations or pricing pressure could erode the flywheel. Additional tailwinds like regulatory approvals or AI-driven surgical improvements may take longer than investors expect, and reimbursement dynamics or competitive threats could drive multiple contraction despite a robust installed base.
Counterpoint: the move may reflect genuine demand fatigue rather than a buy opportunity; if ISRG can't sustain installation growth or convert instrument revenue into outsized earnings, the rebound could stall.
"The multiple contraction reflects higher discount rates, not changing fundamentals, leaving further downside if yields remain elevated."
Claude's framing treats the drop from 70x to 51x P/E as evidence of either prior overvaluation or omitted deterioration. That overlooks the mechanical re-rating all high-duration growth names experienced once the 10-year yield stabilized above 4%. The same rate backdrop Gemini flagged makes sustained 20%+ EPS growth less valuable to investors today than in 2020-21, independent of ISRG's procedure trends or competitive threats.
"Rate-driven multiple compression explains valuation, not stock price decline—ISRG's 30% drop likely signals omitted operational headwinds, not just duration repricing."
Grok's rate-driven re-rating thesis is mechanically sound, but it conflates *valuation compression* with *fundamental resilience*. A 51x multiple in a 4%+ yield environment is rational—agreed. But that doesn't address Claude's core question: *why* did ISRG fall 30% if procedure growth stayed at 17%? Rate moves explain multiple contraction, not absolute drawdowns. If the stock repriced purely on duration, it should track the Nasdaq-100; instead, ISRG underperformed peers, suggesting procedure or margin deterioration the article never discloses.
"The recent drawdown reflects the deliberate, margin-dilutive cost of the da Vinci 5 product transition rather than a decline in fundamental demand."
Claude, your focus on the 30% drawdown misses the elephant in the room: the transition to the da Vinci 5 platform. ISRG is currently absorbing significant R&D and manufacturing ramp-up costs for this new system. This cycle is inherently margin-dilutive in the short term, which the market is punishing. It isn't 'deteriorating guidance' or 'hidden risks'—it is the deliberate, capital-intensive cost of maintaining the moat against Medtronic and J&J. The drawdown is a structural investment, not a fundamental failure.
"Upgrade conversion rate of da Vinci 5 within 2-3 years is the critical unknown; a slow ramp could deepen margin pressure beyond 2026."
Responding to Gemini: you frame the da Vinci 5 as a near-term margin drag; the real risk is timing, not inevitability. If upgrade uptake lags, the annuity from instruments/services may fail to offset R&D/mfg costs, pressuring margins and 2026 outlook. Open-architecture entrants could erode replacement-part pricing more than you imply. The critical unknown is upgrade conversion rate within 2-3 years; a slow ramp could be a deeper bear case than a temporary drag.
Despite strong fundamentals like 75% recurring revenue and 17% procedure growth, the panel is cautious due to high valuation (51x forward P/E), potential slowdown in procedure volumes, rising competition, and the risk of margin compression from new robotic platforms.
None explicitly stated.
High valuation and potential slowdown in procedure volumes or margin compression due to competition.